By Dr. Asnat Raziel, bariatric surgeon specializing in obesity treatment, metabolic health and healthy longevity; Director of the Multidisciplinary Center for Obesity Treatment, Assia Medical, Assuta Ramat HaChayal, Tel Aviv
The OBT-676 pill: news from the lab at ObesityWeek
The OBT-676 pill is an investigational obesity pill that tries to combine several different hormones in a single tablet. The US company Oban presented it this week at ObesityWeek, the American obesity congress in Washington. In rats with obesity, the pill reduced body weight by up to 17% within 28 days. It is important to say this up front: these are animal data only. No one has tested the pill in people yet, and regulators have not approved it.
Why researchers want a pill that combines hormones
Medications such as Wegovy and Mounjaro act on one or two gut hormones. In recent years, researchers have been adding more hormones to the mix. For example, amylin, a satiety hormone made by the pancreas, is now being studied together with GLP-1 drugs. I wrote about this in detail in my review of amylin-based drugs. However, most of these combination treatments are injections. That is why many companies are trying to develop a small molecule that people can swallow as a pill.
How the OBT-676 pill works
According to the company’s press release, the pill fully activates the amylin and calcitonin receptors. At the same time, it partially activates the receptors for three other hormones: GLP-1, GIP and glucagon. In other words, the company designed one molecule to act on five pathways of satiety and metabolism. The company calls this combination DACRA/Triple-G. The company presented the data as a late-breaking abstract, meaning new research that the meeting accepted after its regular deadline.
What the rat study found
The researchers gave the pill once a day for 28 days to rats with diet-induced obesity. Body weight fell by up to 17%, and the weight loss was rapid and sustained. In addition, visceral fat, the fat that surrounds the abdominal organs, dropped by up to 42.5%. Liver fat also decreased. Finally, a glucose tolerance test on day 29 showed good blood sugar control and improved insulin sensitivity.
What the data leave out
On the other hand, the release did not report the doses, the number of rats or the control group. The company’s CEO, Dr. Derek Chalmers, claimed that the pill’s efficacy is on par with investigational injections that researchers are already testing in people. Still, that is the company’s claim, not a head-to-head comparison. Also, the company has not yet published the full abstract, and no peer review has taken place.
Also at the meeting: a long-acting injection from Prolynx
Prolynx, a California company, presented new data on its long-acting injections at the meeting. The company attaches the drug to tiny gel microspheres that release it slowly. It described the method in an earlier rat study. The researchers measured a half-life of more than a month for a product that combines GLP-1 and GIP. The goal is a monthly injection at first, and later one every three months. Here too, these are animal data only. I covered this development, along with Ambrosia’s weekly pill, before the meeting in my article on Kailera’s new drugs.
What the OBT-676 pill means for patients
The bottom line is that this is very early research. Results in rats do not always carry over to people. So it will take years to learn whether the OBT-676 pill is safe and effective. Meanwhile, effective pills already exist today, such as Foundayo and the Wegovy pill. In parallel, researchers are already testing other new pills in people, for example the aleniglipron pill and the BLX-7006 pill.
The bottom line
The direction is clear: the next generation of obesity treatments aims to make life easier for patients and to act on several pathways at once. The OBT-676 pill is one example, but for now it is a promising idea in the lab only. To learn more, read about other lab advances from the meeting. If you are considering treatment, talk with a doctor who specializes in obesity.
This article provides general information only and is not a substitute for personal medical advice.
References
Oban BioPharma Announces Presentation of Late-Breaking Abstract at Obesity Week® 2026
The data are based on the companies’ press releases; the full abstracts have not yet been published.




